



# Risk Of Bias Assessment

## Supplemental Multimedia Component 1. Risk Of Bias Assessment - Total




**Supplemental Multimedia Component 2. Risk Of Bias Assessment – Resolution – Surgical excision vs. Topical Pharmacotherapy**

Resolution – Surgical excision vs Topical pharmacotherapy




**Supplemental Multimedia Component 3. Risk Of Bias Assessment – Resolution – IFN vs. 5-FU**

Resolution – IFN vs. 5-FU




**Supplemental Multimedia Component 4. Risk Of Bias Assessment – Resolution – IFN vs. MMC**

Resolution – IFN vs. MMC




**Supplemental Multimedia Component 5. Risk Of Bias Assessment – Recurrence – Surgical excision vs. Topical Pharmacotherapy**




**Supplemental Multimedia Component 6. Risk Of Bias Assessment – Recurrence – IFN vs. 5-FU**

Recurrence – IFN vs. 5-FU




**Supplemental Multimedia Component 7. Risk Of Bias Assessment – Recurrence – IFN vs. MMC**

Recurrence – IFN vs. MMC



**Supplemental Multimedia Component 8. Risk Of Bias Assessment – Complications Pain – Surgical excision vs. Topical Pharmacotherapy**


Complications Pain – Surgical excision vs. Topical pharmacotherapy






## Supplemental Multimedia Component 9. Risk Of Bias Assessment – Complications Hyperaemia – Surgical excision vs. Topical Pharmacotherapy

Complications Hyperaemia –Surgical excision vs. Topical pharmacotherapy




**Supplemental Multimedia Component 10. Risk Of Bias Assessment – Complications Dry Eye – Surgical excision vs. Topical Pharmacotherapy**

Complications Dry Eye – Surgical excision vs. Topical pharmacotherapy




**Supplemental Multimedia Component 11. Risk Of Bias Assessment – Complications Systemic Side effects – Surgical excision vs. Topical Pharmacotherapy**

Complications Systemic side effects –Surgical excision vs. Topical pharmacotherapy




## Supplemental Multimedia Component 12. Risk Of Bias Assessment – Complications Hyperaemia – IFN vs. MMC

Complications Hyperaemia – IFN vs. MMC




### Supplemental Multimedia Component 13. Risk Of Bias Assessment – Complications Dry Eye – IFN vs. MMC

Complications Dry Eye – IFN vs. MMC




**Supplemental Multimedia Component 14. Risk Of Bias Assessment – Complications Keratopathy – IFN vs. MMC**

Complications Keratopathy –IFN vs. MMC




**Supplemental Multimedia Component 15. Risk Of Bias Assessment – Complications Pain – IFN vs 5-FU**

Complications Pain – IFN vs. 5-FU



**Supplemental Multimedia Component 16. Risk Of Bias Assessment – Complications Hyperaemia – IFN vs. 5-FU**


Complications Hyperaemia – IFN vs. 5-FU






**Supplemental Multimedia Component 17. Risk Of Bias Assessment – Complications Dry Eye – IFN vs. 5-FU**

Complications Dry Eye – IFN vs. 5-FU



**Supplemental Multimedia Component 18. Risk Of Bias Assessment – Complications Keratopathy – IFN vs. 5-FU**

Complications Keratopathy –IFN vs. 5-FU




## Supplemental Multimedia Component 19. GRADE


Question: Topical pharmacotherapy compared to Surgical excision for OSSN

| Certainty assessment |              |              |               |              |             |                      | No of patients          |                   | Effect            |                   | Certainty | Importance |
|----------------------|--------------|--------------|---------------|--------------|-------------|----------------------|-------------------------|-------------------|-------------------|-------------------|-----------|------------|
| No of studies        | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Topical pharmacotherapy | Surgical excision | Relative (95% CI) | Absolute (95% CI) |           |            |

### Resolution

|   |                       |                      |             |             |                      |      |               |               |                                  |  |   |          |
|---|-----------------------|----------------------|-------------|-------------|----------------------|------|---------------|---------------|----------------------------------|--|---|----------|
| 4 | observational studies | serious <sup>a</sup> | not serious | not serious | serious <sup>b</sup> | none | 77/79 (97.5%) | 79/80 (98.8%) | <b>OR 0.79</b><br>(0.13 to 4.74) | <b>3 fewer per 1 000</b><br>(from 76 fewer to 10 more) | <br>Very low | CRITICAL |
|---|-----------------------|----------------------|-------------|-------------|----------------------|------|---------------|---------------|----------------------------------|--|---|----------|

### Recurrence

|   |                       |                      |             |             |                      |      |             |             |                                  |  |   |          |
|---|-----------------------|----------------------|-------------|-------------|----------------------|------|-------------|-------------|----------------------------------|--|---|----------|
| 4 | observational studies | serious <sup>c</sup> | not serious | not serious | serious <sup>b</sup> | none | 4/79 (5.1%) | 6/78 (7.7%) | <b>OR 0.75</b><br>(0.21 to 2.61) | <b>18 fewer per 1 000</b><br>(from 60 fewer to 102 more) | <br>Very low | CRITICAL |
|---|-----------------------|----------------------|-------------|-------------|----------------------|------|-------------|-------------|----------------------------------|--|---|----------|

CI: confidence interval; OR: odds ratio

## Explanations

- a. Because all studies are observational
- b. low number of events, width CI
- c. Because all studies are observational